Waltham, MA-based NeurAxon has pulled in $32 million in its second round of venture capital. Delphi Ventures and OrbiMed Advisors, two new investors, led the round. The money is earmarked for advancing the developer's pain therapies.
"NeurAxon's lead candidate, NXN-188, is designed to provide migraine relief through a dual mechanism of action, and we are encouraged by the early indications that this approach may provide significant improvements over current migraine treatments," said Deepa Pakianathan, Ph.D., general partner of Delphi Ventures.
- here's the release for more info